TLR9 and metabolic dysfunction-associated steatohepatitis: TLR-9 is associated with the pathogenesis of non-alcoholic steatosis hepatis (NASH) and is likely a driver for NASH-associated fibrosis, as it has been shown to be expressed in 13.3% of normal liver tissue, 53.3% in mildly fibrotic patients, 80% in cases of cirrhosis and 95% in hepato-cellular carcinoma patients.